Evolent Health Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Evolent Health kazanç ve gelirin sırasıyla yıllık 79% ve 13.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 79% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 8.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

79.0%

Kazanç büyüme oranı

79.0%

EPS büyüme oranı

Healthcare Services kazanç büyümesi30.8%
Gelir büyüme oranı13.7%
Gelecekteki özkaynak getirisi8.6%
Analist kapsamı

Good

Son güncelleme22 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Evolent Health: A Shot At Revival After Market Bruising

Nov 12

Take Care Before Jumping Onto Evolent Health, Inc. (NYSE:EVH) Even Though It's 49% Cheaper

Nov 09
Take Care Before Jumping Onto Evolent Health, Inc. (NYSE:EVH) Even Though It's 49% Cheaper

We Like These Underlying Return On Capital Trends At Evolent Health (NYSE:EVH)

Nov 07
We Like These Underlying Return On Capital Trends At Evolent Health (NYSE:EVH)

Evolent Health (NYSE:EVH) Has A Pretty Healthy Balance Sheet

Sep 19
Evolent Health (NYSE:EVH) Has A Pretty Healthy Balance Sheet

Evolent Health: Let The Bidding Begin

Aug 23

Potential Upside For Evolent Health, Inc. (NYSE:EVH) Not Without Risk

Jul 29
Potential Upside For Evolent Health, Inc. (NYSE:EVH) Not Without Risk

Evolent Health's (NYSE:EVH) Returns On Capital Are Heading Higher

Jul 01
Evolent Health's (NYSE:EVH) Returns On Capital Are Heading Higher

Evolent Health: Recent Pullback, A Buying Opportunity Or Not? (Rating Downgrade)

May 22

These 4 Measures Indicate That Evolent Health (NYSE:EVH) Is Using Debt Reasonably Well

May 05
These 4 Measures Indicate That Evolent Health (NYSE:EVH) Is Using Debt Reasonably Well

Evolent Health, Inc. (NYSE:EVH) Doing What It Can To Lift Shares

Apr 08
Evolent Health, Inc. (NYSE:EVH) Doing What It Can To Lift Shares

Evolent Health (NYSE:EVH) Is Experiencing Growth In Returns On Capital

Mar 12
Evolent Health (NYSE:EVH) Is Experiencing Growth In Returns On Capital

Evolent Health (NYSE:EVH) Takes On Some Risk With Its Use Of Debt

Jan 17
Evolent Health (NYSE:EVH) Takes On Some Risk With Its Use Of Debt

Many Still Looking Away From Evolent Health, Inc. (NYSE:EVH)

Dec 21
Many Still Looking Away From Evolent Health, Inc. (NYSE:EVH)

Evolent Health (NYSE:EVH) Is Looking To Continue Growing Its Returns On Capital

Nov 30
Evolent Health (NYSE:EVH) Is Looking To Continue Growing Its Returns On Capital

A First Evaluation On Evolent Health

Oct 04

Does Evolent Health (NYSE:EVH) Have A Healthy Balance Sheet?

Sep 29
Does Evolent Health (NYSE:EVH) Have A Healthy Balance Sheet?

There's Been No Shortage Of Growth Recently For Evolent Health's (NYSE:EVH) Returns On Capital

Sep 01
There's Been No Shortage Of Growth Recently For Evolent Health's (NYSE:EVH) Returns On Capital

An Intrinsic Calculation For Evolent Health, Inc. (NYSE:EVH) Suggests It's 47% Undervalued

Aug 04
An Intrinsic Calculation For Evolent Health, Inc. (NYSE:EVH) Suggests It's 47% Undervalued

Evolent Health: Business Economics Still Appealing, Reiterate Buy

Jul 19

Cautious Investors Not Rewarding Evolent Health, Inc.'s (NYSE:EVH) Performance Completely

Jun 14
Cautious Investors Not Rewarding Evolent Health, Inc.'s (NYSE:EVH) Performance Completely

Evolent Health (NYSE:EVH) Takes On Some Risk With Its Use Of Debt

May 30
Evolent Health (NYSE:EVH) Takes On Some Risk With Its Use Of Debt

An Intrinsic Calculation For Evolent Health, Inc. (NYSE:EVH) Suggests It's 34% Undervalued

May 02
An Intrinsic Calculation For Evolent Health, Inc. (NYSE:EVH) Suggests It's 34% Undervalued

Evolent Health (NYSE:EVH) Shareholders Will Want The ROCE Trajectory To Continue

Apr 17
Evolent Health (NYSE:EVH) Shareholders Will Want The ROCE Trajectory To Continue

Evolent Health GAAP EPS of $0.11 beats by $0.13, revenue of $382.4M beats by $9.47M

Feb 22

Is Evolent Health (NYSE:EVH) A Risky Investment?

Feb 19
Is Evolent Health (NYSE:EVH) A Risky Investment?

Evolent Health: Strengthening Fundamentals, Investing At High Rates Of Return

Feb 15

Is Evolent Health, Inc. (NYSE:EVH) Potentially Undervalued?

Feb 01
Is Evolent Health, Inc. (NYSE:EVH) Potentially Undervalued?

Evolent Health (NYSE:EVH) Might Have The Makings Of A Multi-Bagger

Jan 14
Evolent Health (NYSE:EVH) Might Have The Makings Of A Multi-Bagger

Evolent spikes as Humana partnership expands

Jan 12

Is Evolent Health, Inc. (NYSE:EVH) Trading At A 49% Discount?

Dec 27
Is Evolent Health, Inc. (NYSE:EVH) Trading At A 49% Discount?

Evolent Health offered $23.5M class action securities settlement

Sep 19

Evolent Health's (NYSE:EVH) Returns On Capital Are Heading Higher

Sep 18
Evolent Health's (NYSE:EVH) Returns On Capital Are Heading Higher

Kazanç ve Gelir Büyüme Tahminleri

NYSE:EVH - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20263,3565522322311
12/31/20252,935518818015
12/31/20242,560-8105214
9/30/20242,464-10493134N/A
6/30/20242,354-106145176N/A
3/31/20242,176-141129155N/A
12/31/20231,964-142114143N/A
9/30/20231,790-1125589N/A
6/30/20231,632-77-2125N/A
3/31/20231,483-40-1038N/A
12/31/20221,352-19-59-12N/A
9/30/20221,218-4-2519N/A
6/30/20221,088-193567N/A
3/31/2022990-24129N/A
12/31/2021908-301139N/A
9/30/2021906-45-67-41N/A
6/30/2021923-68-131-106N/A
3/31/2021918-261-74-44N/A
12/31/2020925-328-48-16N/A
9/30/2020915-515-2510N/A
6/30/2020895-504-2614N/A
3/31/2020870-334-76-37N/A
12/31/2019687-304-87-43N/A
9/30/2019803-121-126-81N/A
6/30/2019733-107-85-42N/A
3/31/2019685-86-67-22N/A
12/31/2018627-53-190-21N/A
9/30/2018548-49-2710N/A
6/30/2018506-49N/A-8N/A
3/31/2018468-56N/A-18N/A
12/31/2017435-61N/A-28N/A
9/30/2017409-65N/A-55N/A
6/30/2017362-64N/A-51N/A
3/31/2017311-55N/A-49N/A
12/31/2016254-160N/A-36N/A
9/30/2016212-146N/A-20N/A
6/30/2016192-147N/A-35N/A
3/31/2016146220N/A-39N/A
12/31/201597330N/A-18N/A
9/30/201551322N/A-12N/A
6/30/201510329N/A-6N/A
3/31/2015N/A-37N/A4N/A
12/31/2014N/A-31N/AN/AN/A
9/30/201413-29N/A-9N/A
12/31/2013262N/A-14N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EVH önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: EVH önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: EVH önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: EVH şirketinin gelirinin (yıllık 13.7% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: EVH şirketinin gelirinin (yıllık 13.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: EVH 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 8.6 %).


Büyüyen şirketleri keşfedin